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Objectives: We evaluated azacitidine (VidazaH) safety and efficacy in patients with myelodysplastic
syndrome (MDS), acute myeloid leukaemia (AML), and chronic myelomonocytic leukaemia (CMML), in a
real-life setting. Treatment response, dose, and schedule were assessed.
Methods: This non-interventional, post-marketing survey included 49/50 patients receiving azacitidine at 14
Belgian haematology centres from 2010–2012. Treatment-emergent adverse events (TEAEs), including
treatment-related TEAEs, and serious TEAEs (TESAEs) were recorded throughout the study. Treatment
response [complete response (CR), partial response (PR), haematological improvement (HI), stable
disease (SD), treatment failure (TF)) and transfusion-independence (TI) were evaluated at completion of a
1-year observation period (1YOP) or at treatment discontinuation, and overall survival (OS), at study
conclusion.
Results: The median age of patients was 74.7 (range: 43.9–87.8) years; 69.4% had MDS, 26.5% had
primary or secondary AML, and 4.1% had CMML. Treatment-related TEAEs, grade 3–4 TEAEs, and
TESAEs were reported in 67.3%, 28.6%, and 18.4% of patients, respectively. During 1YOP, patients
received a median of 7 (1–12) treatment cycles. Treatment response was assessed for 38/49 patients.
Among MDS and CMML patients (n529), 41.4% had CR, PR, or HI, 41.4% had SD, and 17.2% had TF.
Among AML patients (n59), 44.4% had CR or PR, 33.3% had SD, and 22.2% had TF. TI was observed in
14/32 (43.8%) patients who were transfusion-dependent at baseline. Median (95% confidence interval) OS
was 490 (326–555) days; 1-year OS estimate was 0.571 (0.422–0.696).
Conclusions: Our data support previous findings that azacitidine has a clinically acceptable safety profile
and shows efficacy.
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Introduction
Myelodysplastic syndromes (MDSs) are haemato-
poietic stem cell disorders characterized by ineffective
haematopoiesis and peripheral blood cytopenias.1–4
The median age at MDS diagnosis is §70 years.5–7
MDS prognosis depends on disease risk features
assessed by the International Prognostic Scoring
System (IPSS): patients with low or intermediate-1
(Int-1) IPSS scores have a median overall survival (OS)
of several years, whereas patients with intermediate-2
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(Int-2) or high IPSS scores have a median OS of
approximately 4 months.8 In total, 30–50% of
MDS cases progress to acute myeloid leukae-
mia (AML).9–11 Chronic myelomonocytic leukaemia
(CMML), initially classified morphologically as a
MDS by the French–American–British cooperative
group,12 was later classified by the World Health
Organization (WHO) (2008) as a mixed MDS/
myeloproliferative neoplasm;4 MDS with 20–30%
bone marrow (BM) blast cells was classified as AML
by the WHO.4 Similarly to MDS, CMML and AML
are also commonly diagnosed later in life.13
Currently, the only curative option for MDS is
allogeneic haematopoietic stem cell transplantation
(allo-HSCT).14–17 However, due to high treatment-
related morbidity and mortality, this procedure is
limited to young patients with good performance
status. Thus, since MDS is a disease of the elderly,
only a minority of MDS patients are transplant
candidates.8,18,19
In a phase III randomised trial (AZA-001), the
OS of higher-risk MDS patients (Int-2 or high-
risk; IPSS51.5–2 or §2.5, respectively) was signifi-
cantly prolonged upon treatment with a pyrimidine
nucleoside analogue, azacitidine (VidazaH; Celgene
Corporation, Summit, NJ, USA), compared with
conventional care (median OS: 24.5 vs. 15.0 months;
P50.0001).20 These findings led to the approval of
azacitidine by the European Medicines Agency
(EMA) in December 2008 for treatment of Int-2
and high-risk MDS (according to IPSS), AML with
20–30% BM blasts (according to WHO 2008), and
CMML with 10–29% BM blasts and no myelopro-
liferative syndrome (i.e. ,13 000/ml white blood cells)
for patients who are not transplant eligible and who
have not received previous therapies. The indications
for azacitidine treatment, as well as the reimburse-
ment criteria, have been recently described in detail in
Meers et al.21
To date, post-marketing data assessing the safety
and efficacy of azacitidine in real-life settings
have been limited. Here, we report the results of a
real-life ‘Belgian non-interventional post-marketing
survey in MDS, AML or CMML patients treated
with Azacitidine evaluating Safety and Efficacy’
(BASE).
Patients and Methods
Study design and setting
In this non-interventional post-marketing survey,
patients were recruited in 14 Belgian haematology
centres from 2010 to 2012. The decision on azaciti-
dine treatment was made prior to the study enrol-
ment. Treatment was prescribed and continued at
discretion of the treating physician according to
Belgian clinical practice. Patients were observed for
approximately 1 year following treatment initiation.
Patients treated for less than 1 year were observed up
to 28 days after the last azacitidine administration.
At study end, survival information was collected for
all patients. Written informed consent was obtained
from all patients before recruitment.
The protocol and associated documents were
reviewed and approved by the National Competent
Authority and National/Local Ethics Committees in
accordance with local regulations. This study was
conducted in accordance with Good Clinical Practice
and all applicable regulatory requirements, including
the Declaration of Helsinki.
Patients and data collection
Adult patients with higher-risk MDS, primary or
secondary AML (based on assessed medical histories
and on laboratory data, including BM biopsy and/or
BM aspirate, peripheral blood count, peripheral
blood smear and BM cytogenetics), or CMML,
treated with azacitidine according to Belgian
reimbursement criteria and who provided written
informed consent, were eligible for the study. Patients
were excluded if they were participating in an inter-
ventional clinical trial at the time of recruitment.
Patient and disease characteristics were collected at
baseline using case record forms (CRFs), completed by
the physician. The following baseline patient charac-
teristics were collected: age, gender, and Eastern Coo-
perative Oncology Group performance status.22 The
following baseline disease characteristics were col-
lected: disease diagnosis according to the WHO 2008
classification,4 time since diagnosis, percentage of BM
blasts, cytopenias, packed red blood cell (PRBC)
transfusion within 8 weeks before treatment initiation,
cytogenetic abnormalities, and IPSS score (assessed for
MDS patients).23
At each treatment cycle, dosing and dose modifica-
tion details, adverse events (AEs), supportive treat-
ments, and haematological parameters were recorded
by the investigator in a CRF.
Study objectives
The primary objective of this real-life study was to
assess the safety of azacitidine in Belgian MDS,
AML, or CMML patients. The secondary objectives
included assessment of the efficacy of azacitidine in
terms of treatment response and OS, and evaluation
of the treatment dose and schedule.
Treatment and administration
Patients were treated with azacitidine according to
the schedule used in Belgian clinical practice: 75 mg/
m2/day for 7 days every 28 days. The decision of
treatment discontinuation was made by the patient or
the investigator. The reason for treatment disconti-
nuation was recorded in the CRF.
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Safety assessment
Treatment-emergent AEs (TEAEs) and serious
TEAEs (TESAEs) were recorded up to 28 days follo-
wing the last treatment dose administered. TEAEs
were defined as AEs with onset at or after the first
treatment administration. TESAEs were defined
as AEs with onset at or after the first treatment
administration that resulted in death, congenital
anomaly or birth defect, persistent or significant
disability/incapacity, were life-threatening or required
hospitalisation or prolongation of hospitalisation.
The severity of all AEs was assessed by the
investigators on a 1–5 scale, according to the
Common Terminology Criteria for Adverse Events
version 4.0.24 Symptoms of grade 3–4 intensity were
defined as AEs resulting in a marked (grade 3) or
significant (grade 4) limitation in activity, and
requiring medical intervention, therapy, or hospitali-
sation. Grade 5 symptoms were defined as AEs
leading to death. The causality of all AEs was
assessed by the investigators. Following an AE, the
decision of treatment discontinuation or treatment
dose reduction was made by the investigators.
TESAEs that had not resolved upon a patient’s
discontinuation of participation in the study were
followed until recovery, recovery with sequelae, non-
recovery (death due to another cause), or death (due
to TESAE).
Treatment administration and exposure variables
The following treatment administration variables
were assessed during the 1-year observation period:
mean dose per treatment day, number of treatment
days/cycle, cycle duration, number of cycles, and
number of cycles with dose interruption or reduction.
Dose interruption was defined as treatment adminis-
tration for ,7 days, and dose reduction as adminis-
tration of ,80% of the planned dose intensity for a
single cycle.
Efficacy assessment
At the end of the 1-year observation period or at
treatment discontinuation, azacitidine efficacy in
terms of treatment response, transfusion independence
(TI), and time-to-treatment discontinuation were
assessed for all evaluable patients (38 patients for
treatment response; 32 for TI; 49 for time-to-treatment
discontinuation). Treatment response was evaluated,
according to the International Working Group 2000
criteria for MDS25 and the revised 2003 criteria for
AML,26 as complete response (CR), CR with incom-
plete blood count recovery (CRi) (AML patients),
partial response (PR), haematological improvement
(HI; MDS, and CMML patients), stable disease (SD),
or treatment failure (TF). Overall treatment response
was defined as achievement of CR, PR, or HI (MDS
and CMML patients) or CR, CRi, or PR (AML
patients). TI was defined as the absence of PRBC
transfusion during 2 consecutive cycles for patients
who had received such transfusion within 8 weeks
before the azacitidine treatment initiation. Time-to-
treatment discontinuation was defined as number of
days between the first treatment dose administration
and treatment discontinuation. Survival was defined in
all evaluable patients as the time between the first
administration date and the last contact alive (per-
formed about 1 year after the treatment initiation of
the last patient enrolled) or date of death. Time-to-
treatment discontinuation and 1-year OS were calcu-
lated using Kaplan–Meier curves. An additional
analysis evaluated the OS according to treatment
response, i.e. in responders, patients with SD and non-
responders. Responders were defined as patients with
CR, PR, CRi, or HI, and non-responders as patients
with TF.
Statistical analyses
All statistical analyses were performed on the safety
cohort, which included all patients who received at
least one treatment dose. Continuous variables were
determined as mean (6standard deviation), median
(range: minimum–maximum), and number of obser-
vations. Kaplan–Meier analysis was used to describe
time-to-event data. All statistical analyses were per-
formed using the SAS package for Windows, version
9.2.
Results
Baseline patient and disease characteristics
Fifty patients treated with azacitidine in routine
clinical practice were recruited. One patient initially
included in the intent-to-treat population was lost to
follow-up; the final safety cohort comprised 49
patients (Fig. 1). The majority of patients (77.5%)
were§65 years old, with a median age of 74.7 (43.9–
87.8) years; 69.4% were male. The Eastern Coope-
rative Oncology Group (ECOG) performance status
was 0 for 24.5%, 1 for 44.9%, and 2 for 18.4% of
patients (Supplementary Material 1 http://dx.doi.org/
10.1179/2295333714Y.0000000102.s1). The WHO
diagnosis was MDS for 34 (69.4%), primary or
secondary AML for 13 (26.5%) and CMML for
two (4.1%) patients. 65.3% of patients had received
PRBC transfusion within 8 weeks before the treat-
ment initiation. The mean time since diagnosis was 10
(614.68) months (Supplementary Material 1 http://
dx.doi.org/10.1179/2295333714Y.0000000102.s1).
Among the 34 MDS patients, 2.9% had refractory
cytopenia with multilineage dysplasia, 32.4% had
refractory anaemia with excess of blasts-1 (RAEB-1),
and 61.8% had RAEB-2. The majority of MDS
patients had .10% BM blasts (55.9%) and poor
karyotype score (44.1%), resulting in an Int-2 IPSS
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score (70.6%) (Supplementary Material 2 http://
dx.doi.org/10.1179/2295333714Y.0000000102.s2). 26.5%
had a normal karyotype and 26.5% had a complex kar-
yotype (Supplementary Table S1 http://dx.doi.org/
10.1179/2295333714Y.0000000102.s1).
Among the 13 AML (20–30% BM blasts) pa-
tients, 7.7% had AML with recurrent cytogenetic
abnormalities, 53.8% had AML with multilineage
dysplasia with prior MDS, and 23.1% had AML
with multilineage dysplasia without prior MDS.
Two of 9 evaluated AML patients (22.2%) had a
normal karyotype and 4 (44.4%) had a complex
karyotype.
Safety
TEAEs were reported in all patients (Table 1). TEAEs
considered by the investigators as causally related
to treatment were reported in 67.3% of patients
(Table 1); the most common were general disorders
and administration site reactions, gastrointestinal
disorders, and haematological complications, reported
in 40.8%, 38.8%, and 30.6% of patients, respectively.
The most common general disorders and administra-
tion site reactions were fatigue and injection site
reactions, reported in 16.3% and 14.3% of patients,
respectively. The most common gastrointestinal dis-
orders were nausea, diarrhoea, and vomiting, reported
in 22.4%, 14.3%, and 12.2% of patients, respectively.
The most common haematological complications were
febrile neutropenia and anaemia, each reported
in 16.3% of patients. Treatment-related grade 3–4
TEAEs were reported in 28.6% of patients (Table 1).
The most common were haematological compli-
cations, gastrointestinal disorders and infections,
reported in 18.4%, 8.2%, and 8.2% of patients,
respectively. The most common haematological com-
plication was febrile neutropenia (14.3% of patients),
and the most common gastrointestinal disorder
was diarrhoea (4.1% of patients). Treatment-related
TESAEs were reported in 18.4% of patients (Table 1);
the most common were haematological complica-
tions and infections, each reported in 12.2% of
patients. TEAEs leading to death or discontinuation,
Table 1 Numbers and percentages of patients with treatment-emergent adverse events or serious adverse events
All (N549), n (%) MDS (N534), n (%) AML (N513), n (%) CMML (N52), n (%)
TEAEs 49 (100.0) 34 (100.0) 13 (100.0) 2 (100.0)
Related* 33 (67.3) 21 (61.8) 10 (76.9) 2 (100.0)
Related grade 3–4 14 (28.6) 10 (29.4) 3 (23.1) 1 (50.0)
TEAEs resulting in TD or death{ 11 (22.4) 8 (23.5) 2 (15.4) 1 (50.0)
TESAE 22 (44.9) 15 (44.1) 6 (46.2) 1 (50.0)
Related* 9 (18.4) 6 (17.6) 2 (15.4) 1 (50.0)
Note: MDS, myelodysplastic syndromes; AML, acute myeloid leukaemia; CMML, chronic myelomonocytic leukaemia; N, number of
patients; n (%), number (percentage) of patients within the category; TEAEs, treatment-emergent adverse events; TD, treatment
discontinuation; TESAEs, treatment-emergent serious adverse events.
*Considered by the investigators to be causally related to treatment.
{Independent of disease progression.
Figure 1 Participant flow. ITT, intent-to-treat; N, number of patients; n, number of patients within the group; MDS,
myelodysplastic syndromes; AML, acute myeloid leukaemia; CMML, chronic myelomonocytic leukaemia; AE, adverse event;
1YOP, 1-year observation period. Other: allogenic stem cell transplantation (4); less than 5% blasts present (1); physician
decision of not giving more than 6 cycles (1); no reimbursement of azacitidine (1).
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independently of disease progression, were reported in
22.4% of patients (Table 1).
Treatment administration and exposure
Within the 1-year observation period, patients received
a median of 7 (1–12) treatment cycles, with a median
cycle duration of 30.5 days and median treatment
duration of 273 days; 28.6% of patients received 12
treatment cycles (Supplementary Material 3 http://
dx.doi.org/10.1179/2295333714Y.0000000102.s3). The
median follow-up time was 272 days; 71.4% of patients
did not complete the 1-year observation period. The
main reasons for treatment discontinuation were AE/
death (37.1%), disease progression (22.9%), and non-
response (14.3%). Other reasons were allogenic stem cell
transplantation, less than 5% blasts present in the BM,
physician decision of not giving more than 6 cycles,
patient decision, and no reimbursement of azacitidine
because of an insufficient IPSS score. For the 13 patients
who discontinued the treatment due to AE/death, 6
discontinued the treatment due to death, and 7 due to
AEs; 24.5% of patients had §1 cycle with dose
reduction and 24.5%§1 cycle with dose interruption.
Efficacy
Treatment response, time-to-treatment
discontinuation and transfusion independence
Treatment response was evaluated for 38/49 patients.
For 11 patients, the best response was not assessed by
the investigators; of those, within the observation
period, 1 patient received 1 cycle, 2–2 cycles, 3–3
cycles, 2–4 cycles, 1–5 cycles, and 2–12 cycles. Two of
these patients completed the 1-year observation
period, and 9 discontinued the study due to: patient
decision (1), AE/death (6), or disease progression (2).
Overall treatment response was achieved in 12/29
(41.4%) MDS and CMML patients and in 4/9 (44.4%)
AML patients (Table 2). Overall, 14/49 (28.6%)
patients completed the 1-year observation period.
The median time-to-treatment discontinuation due to
non-response, disease progression, AE, or death was
308 days for all patients (Fig. 2A), 304 days for MDS
patients, and 329 days for AML patients (Fig. 2B).
Among the 32 patients who were transfusion
dependent before study start, 43.8% became TI; 1
was TI during 2 cycles, 4 during 3 cycles, 3 during 4
cycles, 3 during 5 cycles, 1 during 6 cycles, 1 during 7
cycles, and 1 during 10 cycles.
Overall survival
The median OS (based on date of last contact or date
of death) since the first azacitidine administration was
490 days (95% confidence interval: 326–555) for all
patients (Fig. 3A), 501 days (317–665 days) for MDS
patients and 363 days (115–576 days) for AML pati-
ents (Fig. 3B). The estimate of the 1-year OS pro-
bability was 0.57 (0.42–0.70) for all patients, 0.59
(0.41–0.73) for MDS patients, and 0.46 (0.19–0.70)
for AML patients.
In the additional analysis of the OS according to
the response to treatment, the median OS estimates
were 576 days for responders (n516), 513 days for
patients with SD (n515), and 269 days for non-
responders (n57) (Fig. 3C).
Discussion
Two previously published, phase III randomised clinical
trials showed significantly longer OS and lower rate of
progression to AML in higher-risk (43% Int-2; 46%
high-risk)20 or Int-1 to high-risk (45% Int-1; 27% Int-2;
19% high-risk)27 MDS patients treated with azacitidine
compared to conventional treatments. However, in
routine clinical practice, physicians often deal with
elderly patients with co-morbidities and a poor perfor-
mance status, who are often ineligible for randomised
clinical trials. Therefore, non-interventional surveillance
studies are needed to collect and describe real-life data.
Previous real-life studies assessed azacitidine efficacy in
French [patient-named programme: authorization for
temporary utilization (ATU)], Dutch, Turkish, Italian,
Scottish or Austrian patients with MDS, AML, or
CMML.28–34 The Scottish, Italian and Turkish studies
also evaluated the azacitidine safety profile. The current
survey evaluated safety and efficacy of azacitidine in
Belgian MDS, AML, or CMML patients treated in a
real-life setting.
Table 2 Treatment response
MDS (N527), n (%) CMML (N52), n (%) MDSzCMML (N529), n (%) AML (N59), n (%)
Overall response* 12 (44.4) 0 (0.0) 12 (41.4) 4 (44.4)
CR/CRi 3 (11.1) 0 (0.0) 3 (10.3) 4 (44.4)
PR 3 (11.1) 0 (0.0) 3 (10.3) 0 (0.0)
HI 6 (22.2) 0 (0.0) 6 (20.7) …
SD 11 (40.7) 1 (50.0) 12 (41.4) 3 (33.3)
TF 4 (14.8) 1 (50.0) 5 (17.2) 2 (22.2)
Note: MDS, myelodysplastic syndromes; CMML, chronic myelomonocytic leukaemia; AML, acute myeloid leukaemia; N, number of
patients; n (%), number (percentage) of patients within the category; CR, complete response (MDS and CMML patients); CRi,
complete response with incomplete blood count recovery (AML patients); PR, partial response; HI, haematological improvement; SD,
stable disease; TF, treatment failure.
*For MDSzCMML patients: CRzPRzHI; for AML patients, CRzPRzCRi.
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In this survey, patients were slightly older [median
age: 74.7 (43.9–87.8) years] than patients included in
the previous real-life studies with azacitidine [median
age: 70–73 (20–91 for all studies)] (Table 3).28,29,31–34
Among the MDS patients included in this survey,
there were more Int-2 (70.6%) and less high-risk
patients (20.6%) compared to the French ATU study
(54% Int-2 and 43% high-risk),29 probably due to
Figure 2 Time-to-treatment discontinuation (A) in all patients and (B) in MDS and AML patients. MDS, myelodysplastic
syndromes; AML, acute myeloid leukaemia; N, number of patients.
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Figure 3 Overall survival (A) in all patients, (B) in MDS and AML patients and (C) in patients according to the response to
treatment. MDS, myelodysplastic syndromes; AML, acute myeloid leukaemia; SD, stable disease; N, number of patients.
Responders were defined as patients with complete remission, partial remission, complete remission with incomplete blood
count recovery (acute myeloid leukaemia patients) or haematological improvement. Non-responders were defined as patients
with treatment failure.
Beguin et al. Safety and efficacy of azacitidine in Belgian patients
40 Acta Clinica Belgica 2015 VOL. 70 NO. 1
different treatment strategies or referral patterns. The
majority of MDS patients included in our and the
previous real-life studies had poor karyotype score
and RAEB-2 WHO diagnosis.29,34
The azacitidine safety profile was consistent with
previous findings.20,28,31,33 The most common TEAEs
were general disorders, administration site reactions,
gastrointestinal disorders, and infections. Treatment-
related and grade 3–4 TEAEs were also consistent
with those reported in the AZA-001 trial.20
Belgian patients received azacitidine for a median of
7 (1–12) cycles within the 1-year observation period.
The number of cycles was equivalent to the Italian
study [median: 7 (2–22) cycles; follow-up not reported)
and superior to the French ATU [median: 6 (1–52)
cycles; median follow-up: 26 months], Dutch [median: 5
(1–19) cycles; median follow-up: 13 months], and the
Austrian studies [median: 4 (1–24) cycles; follow-up not
reported).28,29,33,34 However, the ATU and the Dutch
studies included a higher number of high-risk patients,
who are more likely to discontinue treatment earlier due
to haematological complications or death than Int-2
MDS patients.
The majority of Belgian patients received the US
Food and Drug Administration- and EMA-approved
azacitidine schedule (75 mg/m2/day for 7 days every
28 days), and about 25% of patients received shorter
schedules, mostly due to AE/death, disease progres-
sion, and non-response. The ATU study reported a
similar proportion of patients with reduced treatment
schedule (28%).29 In this previous study, a non-
significant trend for reduced OS was observed in
patients receiving reduced schedules. In the Dutch
study, the number of patients with a treatment
response increased with the number of cycles
received.34 Similarly, in a secondary analysis of the
AZA-001 trial, 91% of high-risk MDS patients
responded to treatment within 6 azacitidine cycles
and the continuation of treatment further improved
the response rates.35
In our survey, approximately 42% of patients
(41.4% of high-risk MDS or CMML patients and
44.4% of AML patients) achieved a treatment respo-
nse, which is consistent with findings of the previous
Dutch, French, Italian, and Austrian studies, in which
the overall treatment responses were 48%, 43%, 50%,
and 45%, respectively (Table 3).28,29,33,34 In our survey,
the overall response was higher than that reported in
the Scottish study in patients with MDS or AML
(31%).31 This could be due to the higher number of
azacitidine cycles (median: 7 cycles) compared to the
Scottish study (median: 4 cycles), as the response to
azacitidine may appear only after several treatment
cycles. In our survey, the median OS was 490 days
(16.1 months). This was shorter than the median OS of
24.5 months reported in the AZA-001 trial, but
comparable to the median OS of 13.5, 13, and
15 months observed in the French, Dutch, and Italian
Table 3 Patient characteristics and efﬁcacy of azacitidine — comparison of results from the current and previously
published studies
Study
BASE
Current study
AZA-001
(AZA arm)20
French
(ATU)29 Italian28 Scottish31 Turkish32 Dutch34 Austrian33
Baseline
characteristics
N 49 179 282 20 42 25 90 155
% MDS 69.4 63 78 85 45.2 48.0 52.2 0
% AML 26.5 31 22 15 45.2 32.0 34.4 100
% CMML 4.1 6 0 0 9.5 20.0 13.3 0
Age (years),
median
74.7 69 71 71 72 70 71 73
Efficacy
Treatment
response
N 38
(29 for HI)
179
(177 for HI)
282 20 42 25 90 155
CR{zPRzHI, % 42.1 78 32 50 31.0 64.0 48 45.2
CR{, % 18.4 17 14 NR 9.5 12.0 26 12.9
PR, % 7.9 12 3 NR 0.0 12.0 1 20.6
HI, % 12.2 49 15 NR 21.5 40.0 21 9.0
SD, % 39.5 42 22 20 NR 44.0 19 2.6{
Follow-up,
median (months)
9 21.1 26/41.3* NR 6.0 13 8 NR
OS, median 490 d (16.1 m) 24.5 m 13.5* m 356 d (11.7 m) NR NA 13.0 m 9.8 m
Note: ATU, authorization for temporary utilization; N, total number of patients; %, percentage of patients within the category; MDS,
myelodysplastic syndromes; AML, acute myeloid leukaemia; CMML, chronic myelomonocytic leukaemia; CR, complete response; PR,
partial response; HI, haematological improvement; SD, stable disease; OS, overall survival; d, days; m, months; NR, not reported; NA,
not assessed.
*Additional analysis of the study: Itzykson et al. (2012).30
{Marrow SD with HI.
{CR or CR/CRi (CR with incomplete blood count recovery) or CR/CRi/mCR (marrow CR).
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study, respectively (Table 3).20,28,29,34 The longer med-
ian OS in the AZA-001 trial probably resulted from the
more stringent eligibility criteria of clinical trials
compared with real-life studies. In our survey, patients
considered as responders (CR, PR, or HI) and patients
with SD seemed to have longer survival than non-
responders (19.2 and 17.1 months vs. 8.9 months).
Similarly, in the Dutch study, the OS of responders
was significantly longer than that of non-responders
(16 months vs. 6 months; P,0.001), whereas in the
Austrian study, any kind of response resulted in
significantly longer OS compared to patients without
such response, i.e. marrow response (24.7 months for
CR vs. 15.2 months for marrow SD vs. 2.3 months for
PD) or HI (18.9 months vs. 6.0 months).33,34
Furthermore, an additional analysis of the AZA-001
study evaluating the relationship between treatment
response and OS revealed that OS of patients with
treatment response or HI was significantly improved
compared to non-responders; the OS was also sig-
nificantly higher in patients treated with azacitidine
than in those treated with conventional care.35
The main limitation of our survey is the small
number of patients included and a relatively short
follow-up period (1 year). Our findings describe the
safety and efficacy of azacitidine treatment in this
group of patients and must be interpreted cautiously.
Our data are in line with those from previous real-life
studies and support findings from trials that suggest
that azacitidine prolongs the survival of MDS, AML,
and CMML patients.
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